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people in developed countries consume about 35% of
their energy as fat, about 10 g/day of salt, and about 0.2
mg/day of folate, and nearly everyone is exposed to the
risks of road injuries.
The chief merit of the increasingly popular
convenience foods is their convenience. Individuals
have little influence over their composition. Even foods
that are described as being healthy can be high in sugar
and salt, counterbalancing any benefit from added
micronutrients, such as folic acid. But discouraging the
use of convenience foods is not practical; we need col-
lective action to reduce the amounts of salt, sugar, and
saturated fat in foods, and a sensible policy on portion
sizes in restaurants.
Of course, individuals have some choice, but for
most people safety and health are minor
determinants—value for money, convenience, and
fashion rank much higher. Safety and health have to be
part of the fabric of society, determined by experts with
specialist knowledge, and translated into policies by
governments, acting on our behalf. For years we have
unquestioningly accepted the addition of iodide to
table salt, to prevent thyroid disease; the prevention is
silent. Charges of paternalism and pejorative labels
such as “nanny state,” with the false innuendo that we
are being controlled against our wishes, are unhelpful
because effective public health needs to be integrated
into the infrastructure of society. We depend on
governments and professionals to ensure that our lives
are as healthy and as free as possible. Governments
have the main responsibility and authority for
maintaining public health, through education, regula-
tion, legislation, and taxation. Not all decisions will be
right, but it is not hard to ensure that most are and,
given new knowledge, to correct those that are not.
An advisory role is not enough. Public health in
countries such as Britain needs a stronger executive
role, relatively free of short term political considera-
tions. Watching our children (and ourselves) becoming
overweight and claiming that it is all about choice is a
denial of everything that public health and preventive
medicine is about, and a denial of what makes a society
civilised and worth belonging to. Public health and
individual choice can flourish together, but the former
should not be driven by the latter.
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Detection, verification, and quantification of adverse drug
reactions
Bruno HCh Stricker, Bruce M Psaty
The current system of verifying and quantifying adverse reactions to new drugs is too disparate.
Epidemiological studies for testing a hypothesis have a part to play in protecting the public from the
harmful effects of new drugs
Although some will question the use of the term
experiment on formal grounds, most experts will likely
agree that the widespread marketing of a new drug is
in fact a large experiment on a population. This is
especially the case when it concerns a novel molecular
entity with potentially a new set of clinical experiences.
As the marketing of new drugs includes the discovery
of adverse effects, the public’s health would be best
protected by a complementary set of techniques for
the detection, verification, and quantification of safety
issues. Yet the current approach to this is scattered and
disappointing.We discuss why healthcare professionals
are not aware of all safety problems of a drug at its
introduction and why pharmacoepidemiology should
complement the indispensable observational method
of case reporting.
Sources and selection criteria
Our review is based on a search of PubMed using the
terms adverse effect, adverse reaction, ADR, adverse
event, adverse reaction monitoring, pharmacovigi-
lance, cohort study, and case-control study. This yielded
several thousand papers from which we excluded indi-
vidual case reports and case series. From a list of
cohort and case-control studies, we picked some recent
examples of pharmacoepidemiological studies of
adverse events with databases. We used the references
from 50 of the most recent reviews, to gather the most
important papers on this subject.
Limitations of clinical trials
Before drugs are marketed, they are extensively tested
in animals and in clinical trials in humans. These tests
tell much about the drug’s efficacy but for several
reasons relatively little about safety (box).
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Good economical reasons preclude an endless
quest for research before drugs are registered. Such
research would make the development of drugs
expensive, a price that ultimately is paid by the
consumer.1 More effort therefore should be put into
researching the safety of drugs after marketing,
especially in the evidence-free zone when drugs are
first launched.2
Protecting society against the adverse effects of
drugs requires early detection, valid verification, and
quantification, which include assessing the frequency
and severity of adverse events, dose relations, the time
course, and susceptibility factors.3
In daily practice many signals of a potential adverse
event are not followed by a systematic process of verifi-
cation and quantification. One reason for this may be
the transitional period between the signal of a problem
and its confirmation. At this point every sensible
professional response is open to discussion. If the
problem is highlighted by a single case report,
attention may fade; even if similar signals are produced
by other case reports, the likelihood of a causal relation
is often just debated unless more evidence emerges.
Subsequent well designed epidemiological studies may
provide additional verification. They also fulfil the need
for quantification of the adverse effect. Whether such
studies are performed usually depends on the
initiatives of scientific groups with an interest in the
topic. Another reason why safety issues may not be
pursued systematically is related to who has the
responsibility. Formally, liability rests with the pharma-
ceutical company, which acts as marketing authorisa-
tion holder, but as it does not have an economic
interest in detecting safety issues it may lack incentive
to investigate problems. Additionally, many problems
related to a drug are caused by class effects, such as
extrapyramidal effects due to neuroleptics. Then it is
not always possible to blame a particular product or
company. Drug authorities should take responsibility
to safeguard public health in such a situation.
Adverse drug reactions
Detection
Adverse effects cannot be detected without astute pro-
fessional observers. Case reports are among the most
important tools for observational research.4 All people
exposed to a new drug comprise the potential
catchment population for adverse effects. In a country
such as the United Kingdom, with some 60 million
inhabitants, a 1% cumulative exposure to a drug yearly
would equate to 600 000 people using the drug at any
time during that year. A rare adverse effect with an
incidence of 1 in 10 000 might be detected in such a
population, particularly when the adverse effect has a
low background incidence, making it easily recognised.
In the case of phocomelia due to thalidomide, for
instance, recognition should have been easy but
because of the unfamiliarity with drug safety problems
at that time it took several years to identify a causal
relation.5 When an adverse effect is non-specific and
has an appreciable background incidence, detection is
more difficult. Similarly, it may be difficult to detect an
adverse effect that is indistinguishable from the disease
being treated—for example, arrhythmia as an adverse
effect of antiarrhythmics. Such adverse effects may
therefore remain unnoticed. One of the most common
reasons for withdrawal of drugs from the market is
hepatitis, which has a high background incidence mak-
ing it potentially difficult to determine a causal
relation.6
Voluntary reporting
Despite these problems in detecting genuine adverse
effects, voluntary reporting of adverse reactions by
clinical observers is inexpensive and effective. Basically,
there are two systems. The first is a virtual one and
relates to all correspondence and short reports in the
medical literature. The second consists of national and
international adverse drug reaction monitoring
centres.
The medical literature
The medical literature is probably by far the most
effective system for initial detection because case
reports are detailed, assessed for quality by reviewers,
mostly independent from commercial incentives, and
open to interested parties. The collaborative output of
the 20 largest medical journals in highlighting a new
problem by a single case report easily outclasses every
other system. Fourteen of 18 important adverse drug
reactions were shown to be detected and verified by
voluntary reporting, mostly through the literature.7 Of
47 anecdotal reports published in 1963 in four major
general medical journals, 35 were clearly correct, which
seems to be satisfactory.8 Not all published case reports
represent genuine adverse reactions as there is always
the risk of false positive signals.8 Despite this, the medi-
cal literature is a highly efficient warning system for
new adverse reactions, and often recognises rare events
and people at high risk.9 10
Monitoring centres
The second system comprises national adverse
drug reaction monitoring centres and the WHO
Collaborating Centre for International Drug
Monitoring. These are not open to third parties such
as consumers, patients, and healthcare professionals.
Most of these systems work with a yellow card scheme,
which can be productive if active and well qualified
staff considers the detection of adverse reactions as
its primary objective. Such monitoring centres are,
Limitations of most clinical trials in
highlighting a drug’s safety
Homogeneous populations
Most trials assess relatively healthy patients with only
one disease and mostly exclude specific groups such as
pregnant women, children, and elderly people
Sample size
Small sample size (up to 1000 patients) reduces the
chance of finding rare adverse effects
Limited duration
Trials of short duration preclude the discovery of long
term consequences such as cancer
Inability to predict the real world
Drug interactions can be substantial in a population as
patients may take drugs concomitantly, a situation that
can almost never be predicted from clinical trials
Education and debate
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however, often understaffed, work in isolated non-
academic environments, have all kinds of responsibili-
ties for regulation, and are overwhelmed by reports
from the pharmaceutical industry. Consequently there
is little time for analysing the reports on adverse reac-
tions sent in by doctors. The legal requirements for
reporting adverse events to the Food and Drug
Administration and European Medicines Evaluation
Agency result in vast numbers of reports, all of which
have to be processed. Many of these have a low likeli-
hood of a causal relation. When it is likely that the lit-
erature produces really new signals in which more
than 50% are causally related, most accounts of the
systems that accumulate reports from industry consist
of either known adverse reactions or unrelated
adverse events. Considering the enormous investment
in human resources in industry and government to
run this system, efficiency is low. As in the end the cost
will inevitably be paid by health insurance systems and
patients, the price of drugs will further increase in the
future.
Hypothesis generating signals
Over the past 30 years attempts have been made to
enhance the recognition of adverse effects by “data
dredging” or “data mining.” The contribution of such
techniques to detecting adverse reactions has been
modest. When substantial numbers of reports are
available, however, comparing the proportion of
reports of an adverse effect with similar drugs may
provide strong hypothesis generating signals, such
as for rhabdomyolysis associated with cerivastatin.11
Such comparison may even facilitate some sort of
hypothesis testing relative risk assessment.12 13 The
validity of such techniques, however, is probably much
lower than that of formal designs of epidemiological
studies.
The originally embraced technique of prescription
event monitoring has proved more difficult than
expected.14 Use of research databases such as the Gen-
eral Practice Research Database for the detection of
adverse effects by generating an hypothesis has had
only limited success. It seems better to restrict the use
of such databases to hypothesis-testing epidemiologi-
cal studies.
Verification and quantification
As soon as an adverse reaction is signalled, a
hypothesis is raised that requires formal testing.
Relevant questions are how often the adverse reaction
occurs and how many times the risk of the adverse
effect is increased by the drug.
To this end the observational designs of the cohort
study and the case-control study have proved useful.15
Cohort studies are particularly useful for uncom-
monly used drugs but are less useful if the disease
being assessed is rare. Case-control studies are
efficient for studying rare diseases but require that the
drug is commonly used. An example of a successful
case-control study was the determination of an
association between vaginal carcinoma of the female
offspring of women who had been treated with
diethylstilbestrol during pregnancy.16 The authors
were able to show the association with only eight cases
and 40 controls.
Databases used by pharmacoepidemiological studies to test hypotheses. Values are relative risks (95% confidence intervals) unless
stated otherwise
Study Database Drug Adverse effect Risk; comparator
Garcia Rodriguez et alw1 General Practice Research
Database
Amoxicillin-clavulanic acid Hepatic injury 6.3 (3.2 to 12.7); amoxicillin
alone
Jick et alw2 General Practice Research
Database
Appetite suppressants Cardiac valve regurgitation Risk 35/10 000 users (16.4 to
76.2) of fenfluramine or
dexfenfluramine compared with
0/10 000 non-users
Zornberg and Jickw3 General Practice Research
Database
Antipsychotics Idiopathic venous
thromboembolism
7.1 (2.3 to 22.0); non-use
Meier et alw4 General Practice Research
Database
Postmenopausal oestrogens Systemic lupus
erythematosus
2.8 (1.3 to 5.8); non-use
Van der Linden et alw5 General Practice Research
Database
Fluoroquinolones Achilles tendon rupture 4.3 (2.4 to 7.8); non-use
Derby et alw6 General Practice Research
Database
Flucloxacillin Cholestatic hepatitis Risk 7.6/100 000 users (3.6 to
13.9) as against 2.1/100 000
users of oxytetracycline
Straus et alw7 Integrated Primary Care
Information Project
Antipsychotics Sudden cardiac death 3.3 (1.8 to 6.2); non-use
Herings et alw8 Pharmaco-morbiditeitskoppeling Angiotensin converting enzyme
inhibitors
Hypoglycaemia 2.8 (1.4 to 5.7); non-use
Ray et alw9 Tennessee Medicaid Benzodiazepines Nocturnal falls 3.0 (2.3 to 3.8); non-use
Ray et alw10 Tennessee Medicaid Tricyclic antidepressants
(>300 mg daily)
Sudden cardiac death 2.5 (1.04 to 6.1); non-use
Summary points
More effort should be put into researching the
safety of drugs after marketing
In daily practice many signals of a potential
adverse event are not followed by a systematic
process of verification and quantification
The medical literature is probably by far the most
effective system for initial detection of adverse
reactions to drugs
The current emphasis on the costly procedures of
mandatory reporting should shift towards
epidemiological studies for testing a hypothesis
Education and debate
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Well designed cohort or case-control studies can
adequately deal with bias and confounding, the two
potential criticisms of these study designs. The issue of
confounding by indication is seldom a problem with
rare adverse effects because such unpredictable effects
are usually not associated with the indication for treat-
ment.17 Although in such studies confounding by con-
traindication may play a part, it leads to a conservative
estimate rather than to an overestimation of the true
risk.18
The cohort and case-control designs can be used to
test hypotheses in de novo field studies. Several
databases facilitate the performance of such studies
with prospectively gathered information on exposure
to a drug and disease (see bmj.com). With these data
resources, several successful pharmacoepidemiological
studies have been performed (table). Unfortunately
and despite the enormous growth of pharmacoepide-
miology and its capabilities, most drugs are withdrawn
on the bases of case reports and case series alone.6
Therefore it is time these databases are used more
consistently for hypothesis testing in research concern-
ing drug safety.
In conclusion, society has the right to be
safeguarded against the adverse effects of new drugs.
The current emphasis on the costly procedures of
mandatory reporting should perhaps shift towards
epidemiological studies for testing a hypothesis. When
particular drug classes and clusters of disease are
involved, regulatory authorities and drug inspectorates
should take the lead to fulfil their primary task of guar-
anteeing safe health care.
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this manuscript.
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Making decisions about benefits and harms of medicines
Trisha Greenhalgh, Olga Kostopoulou, Clare Harries
Even when good scientific data are available, people’s interpretation of risks and benefits will differ
Drug regulatory authorities, such as the Medicines and
Healthcare Products Regulatory Agency in the United
Kingdom and the Food and Drug Administration in
the United States, award product licences by assessing
the balance between benefit and harm. The decision to
revoke a licence generally hangs on evidence of lack of
efficacy or risk of serious adverse effects, taking
account of the seriousness of the condition and the
range of other treatments available.
The authorities work at the level of the whole
population. But individual patients may believe (rightly
in some cases) that a particular regulatory decision is
not in their own best interests, and vociferous
campaigns sometimes result (box 1). Involvement of
patients can be a powerful driver for improving
services.5 But both lay people and professionals are
susceptible to several biases when making health
related decisions (box 2). What can be done to ensure
that the care of individual patients is not compromised
by regulatory decisions intended to protect the
population as a whole, and to encourage objective and
dispassionate decision making in the face of cognitive
biases?
Sources and selection criteria
This article was constructed through multidisciplinary
dialogue between an academic general practitioner
with a keen interest in evidence based and narrative
based decision making, two cognitive psychologists
specialising in risk perception, and an editor with a
background in medical pharmacology. The authors
drew on their own disciplinary perspective, expertise,
and archives. The goal was not to produce an exhaus-
tive overview of any of our areas of expertise but to use
insights from one discipline (psychology) to illuminate
findings from another (drug regulatory decisions).
Two more boxes and further references (w1-w17) are available
on bmj.com
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